Background: The PI3K/AKT/P70S6K pathway is an attractive therapeutic target in ovarian and uterine malignancies because of its high rate of deregulation and key roles in tumor growth. Here, we examined the biological effects of MSC2363318A, which is a novel inhibitor of AKT1, AKT3, and P70S6K. Methods: Orthotopic murine models of ovarian and uterine cancer were utilized to study the effect of MSC2363318A on survival and regression. For each cell line, 10 mice were treated in each of the experimental arms tested. Moreover, in vitro experiments in 21 cell lines (MTT, immunoblot analysis, plasmid transfection, reverse phase protein array [RPPA]) were carried out to characterize underlying mechanisms and potential biomarkers of response. All statistical tests were two-sided. Results: MSC2363318A decreased tumor growth and metastases in multiple murine orthotopic models of ovarian (SKOV3ip1, HeyA8, and Igrov1) and uterine (Hec1a) cancer by reducing proliferation and angiogenesis and increasing cell death. Statistically significant prolonged overall survival was achieved with combination MSC2363318A and paclitaxel in the SKUT2 (endometrioid) uterine cancer mouse model (P < .001). Mice treated with combination MSC2363318A and paclitaxel had the longest overall survival (mean ¼ 104.2 days, 95% confidence interval [CI] ¼ 97.0 to 111.4) compared with those treated with vehicle (mean ¼ 61.9 days, 95% CI ¼ 46.3 to 77.5), MSC2363318A alone (mean ¼ 89.7 days, 95% CI ¼ 83.0 to 96.4), and paclitaxel alone (mean ¼ 73.6 days, 95% CI ¼ 53.4 to 93.8). Regression and stabilization of established tumors in the Ishikawa (endometrioid) uterine cancer model was observed in mice treated with combination MSC2363318A and paclitaxel. Synergy between MSC2363318A and paclitaxel was observed in vitro in cell lines that had an IC50 of 5 mM or greater. RPPA results identified YAP1 as a candidate marker to predict cell lines that were most sensitive to MSC2363318A (R ¼ 0.54, P ¼ .02). After establishment of a murine ovarian cancer model of adaptive anti-angiogenic resistance (SKOV3ip1-luciferase), we demonstrate that resensitization to bevacizumab occurs with the addition of MSC2363318A, resulting in improved overall survival (P ¼ .01) using the Kaplan-Meier method. Mice treated with bevacizumab induction followed by MSC2363318A had the longest
overall survival (mean ¼ 66.0 days, 95% CI ¼ 53.9 to 78.1) compared with mice treated with control (mean ¼ 42.0 days, 95% CI ¼ 31.4 to 52.6) and bevacizumab-sensitive mice (mean ¼ 47.2 days; 95% CI ¼ 37.5 to 56.9). Conclusions: MSC2363318A has therapeutic efficacy in multiple preclinical models of ovarian and uterine cancer. These findings support clinical development of a dual AKT/P70S6K inhibitor.
The PI3K/AKT/mTOR pathway plays a pivotal role in many malignant features involved in tumor pathogenesis (1) . The PIK3CA gene is a commonly mutated oncogene, affecting more than 30% of solid tumors (2) . PTEN, which encodes phosphatase and tensin homolog, is frequently mutated or suppressed, leading to activation of the PI3K/AKT signaling pathway (3) . Ovarian and uterine cancers exhibit alterations in these pathways (4) . Frequent aberrations of this pathway in ovarian cancer include mutations in PTEN (5) or hypermethylation of the promoter (6), loss of heterozygosity at the INPP4B locus (7) , somatic mutations in mTOR and AKT1 (8) , amplification of AKT2 (9) , somatic activating mutations in the PIK3CA gene (10) , and activating mutations in the PIK3R1 gene (11) . Alterations of the PI3K/AKT signaling pathway in ovarian cancers are histology specific; high-grade serous ovarian cancers frequently exhibit amplifications in PIK3CA and in one of the AKT isoforms in up to 20% and 10% to 15% of cases, respectively. Mutations of PIK3CA occur in up to 20% endometrioid and 35% of clear cell ovarian carcinomas. PTEN loss of function mutations are found in 20% of endometrioid ovarian carcinomas (12) . The high prevalence of these molecular alterations in ovarian and uterine cancers represents an important therapeutic opportunity.
Dual AKT/P70S6K inhibition provides a novel therapeutic approach by promoting improved PI3K/AKT pathway inhibition while avoiding the negative effects of AKT activation through compensatory feedback loops, including IRS-1. Additionally, inhibition of two targets further downstream in a hyperactive pathway in solid malignancies could avoid the side effects seen with historical pan-PI3K inhibitors. MSC2363318A (EMD Serono) is a highly kinase-selective, ATP-competitive inhibitor of AKT1, AKT3, and P70S6K (13) . Here, we examine the biological effects of MSC2363318A in orthotopic murine models of ovarian and uterine cancer and identify YAP1 as a potential predictor of response.
Methods
For a full description of the following experiments, please see the Supplementary Methods (available online).
Laboratory Measures
All cell lines were maintained in 5% CO2 at 37 C. Ovarian cancer (A2780, ES2, HeyA8, Igrov1, Ovcar3, Ovcar4, Ovcar5, Ovcar8, Ovca432, and SKOV3ip1) and uterine cancer (AN3CA, Hec1A, Hec1B, Hec265, Ishikawa, KLE, RL95-2, Spec2, SKUT2, and KLE) cell lines were obtained from the American Type Culture Collection. The Ishikawa-luciferase and SKOV3-luciferase cell lines were made following stable transduction with lentivirus carrying the luciferase gene (the lentiviral vector was kindly provided by Craig Logsdon's lab at UT MD Anderson Cancer Center).
In Vivo Models
Six-to eight-week-old female athymic nude mice were purchased from Taconic Farms (Hudson, NY). These mice were cared for according to guidelines set forth by the American Isobologram analyses were performed to calculate a combination index as previously described (38) (39) (40) .
Results

Therapeutic Efficacy of MSC2363318A in Orthotopic Models of Ovarian and Uterine Cancer
First, we carried out a dose-finding experiment with MSC2363318A in an ovarian cancer model (Igrov1), and downstream markers were evaluated 12, 24, and 48 hours after the last dose. (Supplementary Figure 1A , available online). A reduction in expression of downstream p-ribosomal S6 protein and a resultant increase in pAKT 473 (from feedback loops) were observed at doses of 20 and 40 mg/kg, as previously reported (13) .
A maximum tolerated dose experiment was then performed in non-tumor-bearing mice after daily treatment for 14 consecutive days with MSC2363318A with or without paclitaxel. Body weight percentage differences were observed in all groups treated that included MSC2363318A, but weight loss was the least in the monotherapy and combination groups at the 25 mg/ kg dose (Supplementary Figure 1B , available online). Therefore, daily administration of 25 mg/kg was chosen for subsequent experiments. No deaths were observed in any treatment group, and weight was partially recovered during treatment. Next, we carried out a series of experiments to characterize the therapeutic efficacy of MSC2363318A. In the SKOV3ip1 model, tumor growth was statistically significantly decreased in mice treated with MSC2363318A and MSC2363318A with paclitaxel compared with control (control: 1.9 g, SD ¼ 2.0; MSC2363318A: 0.14 g, SD ¼ 0.14, P ¼ .04; MSC2363318A and paclitaxel: 0.12 g, SD ¼ 0.12, P ¼ .03) ( Figure 1A ). Less distant metastases were observed at necropsy in monotherapy and combination therapy groups (Figure 1 , B and C), and reductions in tumor nodules were observed in all treatment groups (Supplementary Figure 1C , available online). There was a 16.8% to 17.6% decrease in mouse body weight, but no noticeable changes in mobility, feeding habits (Supplementary Figure 1D , available online), or deaths were noted during drug treatment. A reduction in downstream p-ribosomal S6 protein was seen in both groups treated with MSC2363318A (Supplementary Figure  1E We also examined the biological effects of MSC2363318A in orthotopic uterine cancer models. Ten days following inoculation of Hec1a cells into the uterine horn, treatment with MSC2363318A and paclitaxel was initiated. In the Hec1a model, tumor growth was statistically significantly decreased in mice treated with MSC2363318A with paclitaxel compared with control (control: 0.98 g, SD ¼ 0.68; MSC2363318A and paclitaxel: 0.14 g, SD ¼ 0.13, P < .001) ( Figure 1D Figure 2H , available online). Given the robust antitumor effects of MSC2363318A-based therapy, we investigated whether survival could be improved by such therapy in the SKUT2 model, which has both PTEN and PIK3CA mutations, leading to increased pathway activation. Survival was analyzed by the Kaplan-Meier method (P < .001 Figure 1G ). To evaluate the effect of MSC2363318A on tumor reduction, mice were injected with luciferase-labeled Ishikawa cells (PTEN mutant) and monitored with IVIS imaging ( Figure 1H ). Regression and stabilization of established tumors were observed in mice treated with combination MSC2363318A and paclitaxel ( Figure 1I ).
Biological Effects of MSC2363318A on Proliferation and Apoptosis
In the SKOV3ip1 model, treatment with combination MSC2363318A and paclitaxel resulted in the greatest reduction of cellular proliferation as determined by Ki67 (mean ¼ 18.0 (Figure 2A 
In Vitro Effect of MSC2363318A in Ovarian and Uterine Cancer Cell Lines
The effect of MSC2363318A on a panel of 10 ovarian cancer cell lines was tested, and IC50 levels ranged from 0.7 to 12.9 mM ( Figure 3A ). Ovca432 was identified as the most sensitive (IC50 ¼ 0.7 mM), and SKOV3ip1 was the most resistant (IC50 ¼ 12.9 mM). In a panel of nine uterine cancer cell lines, the IC50 ranged from 0.0004 to 33.8 mM ( Figure 3B ). AN3CA and KLE were the most sensitive and resistant cell lines, respectively. Cell lines were characterized by mutation status, and we hypothesized that those mutations leading to activation of the PI3K/AKT pathway (such as PTEN-inactivating mutations and PIK3CA mutations) would be the most sensitive to MSC2363318A inhibition ( Table 1) .
Because of the inhibition of tumor growth and proliferation in vivo, we tested these effects in vitro using resistant (defined as IC50 ! 5 mM) ovarian and uterine cancer cell lines, SKOV3ip1 and Ishikawa, respectively. We observed decreased proliferation in both cell lines when treated daily at the previously calculated concentrations that inhibited 20% of cell growth (IC20) and IC50 doses ( Figure 3C ). This was also validated in sensitive (IC50 < 5 mM) ovarian and uterine cancer cell lines, Igrov1 and Hec1b, respectively, at both concentrations (Supplementary Figure 4A , available online). Next, we examined the molecular signaling events involved in the PI3K/AKT pathway after treatment with varying concentrations of MSC2363318A. The expression level of downstream targets, pPRAS-40, and p-ribosomal S6 protein were reduced after treatment of SKOV3ip1 at concentrations above 0.1 mM ( Figure 3D ) between one and 24 hours (Supplementary Figure 4B , available online).
Paclitaxel, in combination with MSC2363318A, contributed to the most profound in vivo effects and was tested in vitro. There was a dose-dependent decrease in cell viability after combination therapy with paclitaxel at the IC20 and IC50 concentrations of MSC2363118A. The combination index (CI), obtained after performing an isobologram analysis, showed synergistic cytotoxicity in Ishikawa and SKOV3ip1 cells with these two treatments ( Figure 3 , E and F). The only other cell line that showed 
YAP1 as a Predictor of In Vitro Response to MSC2363318A
To identify potential markers of response to MSC2363318A, we used RPPAs after treatment of ovarian (Igrov1 and Ovcar5) and uterine (Hec1b, Ishikawa, KLE, and RL95-2) cancer cell lines ( Figure 4A ). Network analysis identified the top networks that were activated in the ratio of resistant to sensitive cell lines (Table 2) . Given the robust in vitro and in vivo effects on angiogenesis, we investigated the upregulated pro-angiogenic signaling molecules by a network overlaid with the ratio of resistant to sensitive total protein changes ( Figure 4B ). After further analysis of only resistant cell lines with and without MSC2363318A treatment, we observed an increase in total YAP1 levels (Supplementary Figure 5A , available online), which was not seen in the sensitive cell lines (Supplementary Figure 5B , available online). We plotted the logarithmic ratio values for YAP1 and pYAP1 from the cell lines using the RPPA data of the treated over untreated ratio ( Figure 4C ). There was higher total YAP1 expression in resistant cell lines, and we validated our findings by immunoblot analysis (Supplementary Figure 5C , available online). Mean YAP1 protein expression from the immunoblot replicates ( Figure 4D ) were evaluated and quantified in a panel of uterine and ovarian cancer cell lines, and a Spearman's correlation was performed (R ¼ 0.54, P ¼ .02), suggesting that more resistant cell lines have higher YAP1 expression and vice versa ( Figure 4E ). To address the role of YAP1 overexpression and resistance to MSC2363318A, we transfected Ovca432, Igrov1, and Hec1b cells with YAP1 or empty vector and characterized them by Because of the emergence of resistance to anti-angiogenesis therapy clinically, we investigated the efficacy of MSC2363318A in models of adaptive resistance. After intraperitoneal establishment of luciferase-labeled SKOV3ip1 ovarian tumors, mice were randomly assigned to two treatment groups: 1) control and 2) bevacizumab treatment. Mice receiving bevacizumab treatment were subsequently divided into bevacizumabsensitive or -resistant groups based on imaging. Bevacizumabresistant mice were defined as those with increased tumor growth as evidenced by increased bioluminescence intensity in previously stable tumor burden ( Figure 6G ). At the emergence of resistance, MSC2363318A was added to bevacizumab treatment. The addition of MSC2363318A at the emergence of resistance halted tumor growth and prolonged survival, as compared with either control or bevacizumab treatment alone using the Kaplan-Meier method (P ¼ .01) ( Figure 6H ). Mice treated with bevacizumab induction followed by MSC2363318A had the longest overall survival (mean ¼ 66.0 days, 95% CI ¼ 53.9 to 78.1) compared with mice treated with vehicle (mean ¼ 42.0 days, 95% CI ¼ 31.4 to 52.6) and bevacizumab-sensitive mice (mean ¼ 47.2 days, 95% CI ¼ 37.5 to 56.9).
Discussion
The key findings in this manuscript are that dual inhibition of AKT and P70S6K has therapeutic efficacy in multiple preclinical models by enhancing cellular apoptosis, inhibiting proliferation, and reducing angiogenesis. Synergy was observed in both ovarian and uterine cancer cell types with the combination of MSC2363318A and paclitaxel. Addition of MSC2363318A to antiangiogenic therapy potentiated the effects of bevacizumab and restored sensitivity in the adaptive resistance setting. Finally, we identified YAP1 as marker that correlates with sensitivity to inhibition with MSC2363318A.
Genetic and/or epigenetic changes lead to activation of the PI3K/AKT signaling pathway in multiple cancers. Additionally, previous analyses have found this pathway to be activated in half of high-grade serous ovarian carcinomas. Uterine cancers harbor the highest rates of PI3K/AKT pathway alterations, including PTEN mutations (15, 16) . Other frequently identified pathway mutations in uterine cancer include PIK3CA (25%-40%), PIK3R1 (15%-25%), and less commonly, AKT1-3 mutations (2%-5%) (17) (18) (19) (20) . PI3K/AKT activation in gynecologic malignancies provides the rationale for development and testing of therapies targeting this signaling pathway.
The first PI3K inhibitors (eg, Wortmannin and LY294002) led to pan-inhibition of this pathway, but their therapeutic potential remained limited (21) . Second-generation PI3K inhibitors targeted specific PI3K isoforms and are being evaluated in preclinical and clinical studies. The third generation inhibitors include dual PI3K/mTOR inhibitors, which targeted PI3K class I isoforms and mTOR complexes 1 and 2 and lead to greater inhibition of the entire pathway (22) . Three isoforms of AKT possess biologic relevance in cancer pathogenesis, and phosphorylation activates multiple downstream signaling cascades including tuberous sclerosis complex 2 (TSC2) protein, tuberous sclerosis 1 (TSC1), mTOR, BAD, and caspase-9 (22, 23) . AKT inhibitors in preclinical and clinical development include perifosine, MK-2206, RX-0201, Erucylphosphocholine, PBI-05204, GSK690693, and XL-418 (23, 24) . XL-418, which inhibited both AKT and P70S6K, was tested in a phase I clinical trial in patients with advanced solid tumors. This study ended because of low drug exposure (NCT00460278). Previous mTOR complex-1 (mTORC1) inhibitors including everolimus or temsirolimus have been efficacious clinically, but their activity may be limited to the AKT pathway feedback loop activation (25, 26) . This is via induction of insulin receptor substrate-1 expression and abrogation of feedback inhibition within the PI3K/AKT pathway, which may cause hypersensitivity to inhibitors of the PI3K/AKT pathway. Inhibition of P70S6K further downstream confers a potential advantage over previously developed PI3K/AKT pathway inhibitors and can overcome activation of AKT in the feedback loop. Consistent with previous reports, MSC2363318A-treated cells have increased pAKT 473 expression, suggesting activation of the phosphorylated substrate, but pPRAS40 was not increased compared with control cells, which suggests successful inhibition of AKT activity. Historical studies have also shown a reduction in pGSK3a/b, providing further evidence of AKT inhibition (13) . Yes-associated protein (YAP) is one of the main downstream effectors of the Hippo signaling pathway, known to play a role in many oncogenic features (27, 28) . Unphosphorylated YAP translocates and accumulates in the nucleus, where it forms complexes with other transcriptional factors, leading to expression of target genes. Phosphorylated YAP promotes its cytoplasmic translocation and degradation. Previous studies have shown that levels and nuclear localization of YAP are elevated in some solid malignancies (29) , including ovarian and endometrial cancer (30, 31) . Downregulation of the Hippo signaling pathway has been shown to promote ovarian cancer growth and is a key tumor suppressor pathway, but also makes ovarian cancer cells resistant to chemotherapy (28) , specifically cisplatin (32) . YAP1 signatures have been identified to be predictors of poor prognosis and survival (32) (33) (34) , as well as those that may benefit from taxane-based chemotherapy (33) . The PI3K/AKT pathway is hypothesized to interact in YAP-mediated drug resistance, and it has been previously shown that YAP is involved in crosstalk between the PI3K/AKT and Hippo signaling pathways (35, 36) . One possible mechanism for the elevated YAP1 expression could be via YAP1-mediated IGF expression and consequent activation of the PI3K/AKT pathway (37) . Patients with ovarian and endometrial tumors with high YAP1 expression and increased PI3K/AKT activation could theoretically benefit the most from MSC2363318A.
The first phase I trial of MSC2363318A in patients with advanced malignancies has recently opened (NCT01971515). Future directions include administration of MSC2363318A as an adjuvant therapy in combination with taxane-based therapy after surgical cytoreduction. Moreover, MSC2363318A monotherapy could be tested in a maintenance therapy setting. Other alternatives include combining MSC2363318A with bevacizumab in patients with adaptive resistance. Finally, the identification of high YAP1 expression identifies those tumors that are most sensitive to inhibition by MSC2363318A. By identifying the subset of patients whose tumors would be most sensitive to dual AKT/P70S6K inhibition, lower treatment doses could be considered, overtreatment of patients who would not benefit could be avoided, and untoward toxicities in patients who will not respond could be prevented.
Our study has some potential limitations. Despite the safety of MSC2363318A in preclinical experiments, unexpected toxicities may be identified in early clinical trials. Further preclinical safety will need to be evaluated prior to future clinical development. In summary, MSC2363318A-based therapy may be therapeutically beneficial to ovarian and uterine cancer patients and YAP1 represents a potential predictive biomarker for sensitivity to this treatment.
